Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 12
Submit an article Journal homepage
800
Views
20
CrossRef citations to date
0
Altmetric
Author's View

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy

Samuel T Workenhe Department of Pathology and Molecular Medicine; McMaster Immunology Research Centre; Institute for Infectious Disease Research; McMaster University; Hamilton, ON Canada
&
Karen L Mossman Department of Pathology and Molecular Medicine; McMaster Immunology Research Centre; Institute for Infectious Disease Research; McMaster University; Hamilton, ON CanadaCorrespondence[email protected]
Article: e27138 | Received 03 Nov 2013, Accepted 08 Nov 2013, Published online: 09 Dec 2013

References

  • Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658 - 70; http://dx.doi.org/10.1038/nbt.2287; PMID: 22781695
  • Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19:329 - 36; http://dx.doi.org/10.1038/nm.3089; PMID: 23396206
  • Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. [Epub ahead of print] Mol Ther 2013; Forthcoming http://dx.doi.org/10.1038/mt.2013.220; PMID: 24048442
  • Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691 - 701; http://dx.doi.org/10.1084/jem.20050915; PMID: 16365148
  • Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54 - 61; http://dx.doi.org/10.1038/nm1523; PMID: 17187072
  • Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573 - 7; http://dx.doi.org/10.1126/science.1208347; PMID: 22174255
  • Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729 - 41; http://dx.doi.org/10.1016/j.immuni.2013.03.003; PMID: 23562161
  • Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860 - 75; http://dx.doi.org/10.1038/nrc3380; PMID: 23151605
  • Workenhe ST, Simmon GJ, Pol JG, Lichty BD, Halford WP, Mossman KL. HSV induced immunogenic oncolysis shapes the adaptive immune response and survival after oncolytic HSV-1 treatment. Mol Ther 2013; PMID: 24048442
  • Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immunotolerance and improves therapeutic efficacy. Cancer Immunol Res 2013; 1:1 - 11

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.